Concepedia

Publication | Closed Access

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

DOI

40

Citations

14

References

2016

Year

Emiliano Calvo, Fadi Braiteh, Daniel D. Von Hoff, Robert R. McWilliams, Carlos Becerra, Matthew D. Galsky, Gayle Jameson, Ji Lin, Scott McKane, Enaksha Wickremsinhe,
Oncology

Abstract

The maximum tolerated dose of LY2603618 combined with gemcitabine was 200 mg/m2, but a fixed LY2603618 dose of 230 mg combined with gemcitabine was selected as the recommended phase II dose.

References

YearCitations

Page 1